» Articles » PMID: 12884243

Innovations in Oligonucleotide Drug Delivery

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2003 Jul 29
PMID 12884243
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Oligonucleotides (ONs) are a new class of therapeutic compounds under investigation for the treatment of a variety of disease states, such as cancer and HIV, and for FDA approval of an anti-CMV retinitis antisense molecule (Vitravene trade mark, Isis Pharmaceuticals). However, these molecules are limited not only by poor cellular uptake, but also by a general lack of understanding regarding the mechanism(s) of ON cellular uptake. As a result, various delivery vehicles have been developed that circumvent the proposed mechanism of uptake, endocytosis, while improving target specific delivery and/or drug stability. This review describes various traditional and novel delivery mechanisms that have been employed to improve ON cellular delivery, cost effectiveness, and therapeutic efficacy.

Citing Articles

A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.

Eker F, Duman H, Akdasci E, Bolat E, Saritas S, Karav S Molecules. 2024; 29(15).

PMID: 39124888 PMC: 11314082. DOI: 10.3390/molecules29153482.


Advancements in application of chitosan and cyclodextrins in biomedicine and pharmaceutics: recent progress and future trends.

Bahavarnia F, Hasanzadeh M, Bahavarnia P, Shadjou N RSC Adv. 2024; 14(19):13384-13412.

PMID: 38660530 PMC: 11041621. DOI: 10.1039/d4ra01370k.


Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.

Chen S, Heendeniya S, Le B, Rahimizadeh K, Rabiee N, Zahra Q BioDrugs. 2024; 38(2):177-203.

PMID: 38252341 PMC: 10912209. DOI: 10.1007/s40259-024-00644-7.


Supramolecular nanomedicines based on host-guest interactions of cyclodextrins.

Tong F, Zhou Y, Xu Y, Chen Y, Yudintceva N, Shevtsov M Exploration (Beijing). 2023; 3(4):20210111.

PMID: 37933241 PMC: 10624390. DOI: 10.1002/EXP.20210111.


Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas.

Gupta R, Salave S, Rana D, Karunakaran B, Butreddy A, Benival D Pharmaceutics. 2023; 15(5).

PMID: 37242677 PMC: 10222274. DOI: 10.3390/pharmaceutics15051435.


References
1.
von der Leyen H, Braun-Dullaeus R, Mann M, Zhang L, Niebauer J, Dzau V . A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer. Hum Gene Ther. 1999; 10(14):2355-64. DOI: 10.1089/10430349950017004. View

2.
STULL R, Szoka Jr F . Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res. 1995; 12(4):465-83. DOI: 10.1023/a:1016281324761. View

3.
Lubrich B, van Calker D, Peschka-Suss R . Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes. Eur J Biochem. 2000; 267(8):2432-8. DOI: 10.1046/j.1432-1327.2000.01255.x. View

4.
Iversen P, Zhu S, Meyer A, Zon G . Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev. 1992; 2(3):211-22. DOI: 10.1089/ard.1992.2.211. View

5.
Loke S, Stein C, Zhang X, Mori K, Nakanishi M, Subasinghe C . Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989; 86(10):3474-8. PMC: 287160. DOI: 10.1073/pnas.86.10.3474. View